Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodolfo Hurle

Showing results (141-150 of 183) with videos related to

Pageof 19
Sort By:
Clinical Genitourinary Cancer|January 16, 2022
Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort AnalysisMatteo Ferro, Sever Chiujdea, Gennaro Musi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 5, 2026
[<sup>68</sup>Ga]PSMA-11 PET/CT vs. mpMRI in patients with a high suspicion of prostate cancer and previous negative biopsy: head to head, parallel, prospective trial (PROSPET-BX)Egesta Lopci, Massimo Lazzeri, Alberto Saita, et al.
European Urology Oncology|June 21, 2024
Clinical Validation of the Intermediate-risk Non-muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group CollaborationFrancesco Soria, Matteo Rosazza, Simone Livoti, et al.
BJU International|January 11, 2025
Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group resultsPietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
World Journal of Urology|April 30, 2022
Neoadjuvant chemotherapy does not increase peri-operative morbidity following radical cystectomyAmandeep Arora, Ahmed S Zugail, Felipe Pugliesi, et al.
The Journal of Experimental Medicine|December 17, 2021
Lipid-loaded tumor-associated macrophages sustain tumor growth and invasiveness in prostate cancerMichela Masetti, Roberta Carriero, Federica Portale, et al.
Urologia Internationalis|July 6, 2018
High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional StudyMatteo Ferro, Mihai Dorin Vartolomei, Francesco Cantiello, et al.
BJU International|March 13, 2026
Risk stratification and conditional recurrence after radical cystectomy: toward adaptive follow-upRoberto Contieri, Alberto Martini, Marc Furrer, et al.
Clinical Genitourinary Cancer|August 6, 2018
Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder CancerMihai Dorin Vartolomei, Matteo Ferro, Francesco Cantiello, et al.
Medicine|October 27, 2015
Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter ExperienceMatteo Ferro, Ottavio De Cobelli, Carlo Buonerba, et al.
Pageof 19

Showing results (141-150 of 183) with videos related to

Sort By:
Pageof 19
Clinical Genitourinary Cancer|January 16, 2022
Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort AnalysisMatteo Ferro, Sever Chiujdea, Gennaro Musi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 5, 2026
[<sup>68</sup>Ga]PSMA-11 PET/CT vs. mpMRI in patients with a high suspicion of prostate cancer and previous negative biopsy: head to head, parallel, prospective trial (PROSPET-BX)Egesta Lopci, Massimo Lazzeri, Alberto Saita, et al.
European Urology Oncology|June 21, 2024
Clinical Validation of the Intermediate-risk Non-muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group CollaborationFrancesco Soria, Matteo Rosazza, Simone Livoti, et al.
BJU International|January 11, 2025
Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group resultsPietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
World Journal of Urology|April 30, 2022
Neoadjuvant chemotherapy does not increase peri-operative morbidity following radical cystectomyAmandeep Arora, Ahmed S Zugail, Felipe Pugliesi, et al.
The Journal of Experimental Medicine|December 17, 2021
Lipid-loaded tumor-associated macrophages sustain tumor growth and invasiveness in prostate cancerMichela Masetti, Roberta Carriero, Federica Portale, et al.
Urologia Internationalis|July 6, 2018
High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional StudyMatteo Ferro, Mihai Dorin Vartolomei, Francesco Cantiello, et al.
BJU International|March 13, 2026
Risk stratification and conditional recurrence after radical cystectomy: toward adaptive follow-upRoberto Contieri, Alberto Martini, Marc Furrer, et al.
Clinical Genitourinary Cancer|August 6, 2018
Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder CancerMihai Dorin Vartolomei, Matteo Ferro, Francesco Cantiello, et al.
Medicine|October 27, 2015
Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter ExperienceMatteo Ferro, Ottavio De Cobelli, Carlo Buonerba, et al.
Pageof 19